Correlation Between Novo Nordisk and Ascletis Pharma

Can any of the company-specific risk be diversified away by investing in both Novo Nordisk and Ascletis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novo Nordisk and Ascletis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Novo Nordisk AS and Ascletis Pharma, you can compare the effects of market volatilities on Novo Nordisk and Ascletis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of Ascletis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and Ascletis Pharma.

Diversification Opportunities for Novo Nordisk and Ascletis Pharma

-0.21

Correlation Coefficient

Novo Nordisk  Ascletis Pharma

Very good diversification

The 3 months correlation between Novo and Ascletis is -0.21. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and Ascletis Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ascletis Pharma and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with Ascletis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ascletis Pharma has no effect on the direction of Novo Nordisk i.e., Novo Nordisk and Ascletis Pharma go up and down completely randomly.

Pair Corralation between Novo Nordisk and Ascletis Pharma

Assuming the 90 days horizon Novo Nordisk AS is expected to under-perform the Ascletis Pharma. But the pink sheet apears to be less risky and, when comparing its historical volatility, Novo Nordisk AS is 7.28 times less risky than Ascletis Pharma. The pink sheet trades about -0.05 of its potential returns per unit of risk. The Ascletis Pharma is currently generating about 0.16 of returns per unit of risk over similar time horizon. If you would invest  24.00  in Ascletis Pharma on December 21, 2024 and sell it today you would earn a total of  80.00  from holding Ascletis Pharma or generate 333.33% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	93.65%
Values	Daily Returns

Novo Nordisk AS  vs.  Ascletis Pharma

Novo Nordisk AS

Risk-Adjusted Performance

Very Weak

Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest conflicting performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.

Ascletis Pharma

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Ascletis Pharma are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile essential indicators, Ascletis Pharma reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Novo Nordisk and Ascletis Pharma

The main advantage of trading using opposite Novo Nordisk and Ascletis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novo Nordisk position performs unexpectedly, Ascletis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ascletis Pharma will offset losses from the drop in Ascletis Pharma's long position.

The idea behind Novo Nordisk AS and Ascletis Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.